PTC Therapeutics received a positive opinion from a European regulator in May for its Duchenne muscular dystrophy (DMD) treatment Translarna and conditional approval in Europe is expected this summer, said the company's CFO Shane Kovacs. Kovacs said the company, which has seen its shares nearly double in price since the May announcement, is currently enrolling a large-scale, placebo-controlled, confirmatory Phase 3 trial for Translarna in nonsense mutation DMD. Furthermore, he said PTC initiated a confirmatory Phase 3 study of Translarna in nonsense mutation cystic fibrosis.

More from Video

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Learn Options Trading from the Najarian Brothers, the Best in the Business

Learn Options Trading from the Najarian Brothers, the Best in the Business

Jim Cramer: Kimberly Clark's Quarter Was Better Than Procter & Gamble's

Jim Cramer: Kimberly Clark's Quarter Was Better Than Procter & Gamble's

Video: Jim Cramer on What Trade Tariffs and Rising Rates Mean for Stocks

Video: Jim Cramer on What Trade Tariffs and Rising Rates Mean for Stocks

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)